Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue 6, 2011, Pages 681-690

  Fury, Matthew G ^a   Pfister, David G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cetuximab; Cisplatin; Head and neck; Metastatic; Paclitaxel; Squamous cancer

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VINBLASTINE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL DECISION MAKING; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CANCER; HUMAN; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PALLIATIVE THERAPY; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SQUAMOUS CELL CARCINOMA; SYSTEMIC THERAPY; TREATMENT RESPONSE;

EID: 79957820976     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0056     Document Type: Review

References (71)

1. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24:2644-2652. (Pubitemid 46628471)
2. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 2010;21(Suppl 7): vii252-vii261.
3. Al-Sarraf M. Chemotherapy strategies in squamous cell carcinoma of the head and neck. Crit Review Oncol Hematol 1984;1:323-355.
4. Deleyiannis FW, Thomas DB, Vaughan TL, Davis S. Alcoholism: independent predictor of survival in patients with head and neck cancer. J Natl Cancer Inst 1996;88:542-549. (Pubitemid 26118725)
5. Karnoven-Gutierrez CA, Ronis DL, Fowler KE, et al. Quality of life scores predict survival among patients with head and neck cancer. J Clin Oncol 2008;26:2754-2760.
6. Kwok J, Langevein SM, Argiris A, et al. The impact of health insurance status on the survival of patients with head and neck cancer. Cancer 2010;116:476-485.
7. Lee JJ, Jeng JH, Wang HM, et al. Univariate and multivariate analysis of prognostic significance of betel quid chewing in squamous cell carcinoma of the buccal mucosa in Taiwan. J Surg Oncol 2005;91:41-47.
8. Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck: an analysis of two Eastern Cooperative Oncology Group randomized trials. Cancer 2004;101:2222-2229. (Pubitemid 39458677)
9. Penel N, Berthon C, Everard F, et al. Prognosis of hypercalcemia in aerodigestive tract cancers: a study of 136 recent cases. Oral Oncol 2005;41:884-889. (Pubitemid 41265946)
10. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. New Engl J Med 2010;363:24-35.
11. Wittes RE, Cvitkovic E, Shah J, et al. CIS-Dichlorodiammineplatinum (II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep 1977;61:359-366. (Pubitemid 8137937)
12. Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 1985;15:283-289. (Pubitemid 15240980)
13. Hong WK, Schaefer S, Issell B, et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer 1983;52:206-210. (Pubitemid 13063158)
14. Grose WE, Lehane DE, Dixon DO, et al. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck: a Southwest Oncology Group Study. Cancer Treat Rep 1985;69:577-581. (Pubitemid 15037515)
15. Kish JA, Weaver A, Jacobs J, et al. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid carcinoma of the head and neck. Cancer 1984;53:1819-1824. (Pubitemid 14127632)
16. Jacobs C, Lyman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992;10:257-263.
17. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cersus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994;5:521-526.
18. Eisenberger M, Hornedo J, Silva H, et al. Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 1986;4:1506-1509. (Pubitemid 17183575)
19. Al-Sarraf M, Metch B, Kish J, et al. Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study. Cancer Treat Rep 1987;71:723-726.
20. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992;10:1245-1251.
21. Forastiere A, Shank D, Neuberg D, et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 1998;82:2270-2274. (Pubitemid 28240836)
22. Dreyfuss AI, Clark JR, Norris CM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996;14:1672-1678. (Pubitemid 26134226)
23. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and cancer (E1395): an Intergroup Trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-3567.
24. Clark JI, Hofmeister C, Choudhury A, et al. Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer 2001;92:2334-2340. (Pubitemid 33029077)
25. Ferrari D, Fiore J, Codeca C, et al. A phase II study of carboplatin and paclitaxel for recurrent and metastatic head and neck cancer. Anticancer Drugs 2009;20:185-190.
26. Moosmann P, Egli F, Stahel RA, Jost L. Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck. Onkologie 2003;26:568-572. (Pubitemid 38056744)
27. Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16:1325-1330. (Pubitemid 28175747)
28. Shin DM, Khuri FR, Glisson BS, et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 2001;91:1316-1323. (Pubitemid 32267043)
29. Janinis J, Papadakou M, Xidakis E, et al. Combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol 2000;23:126-131.
30. Pivot X, Raymond E, Laguerre B, et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 2001;85:649-655. (Pubitemid 32929458)
31. Fury MG, Haque S, Stambuk H, et al. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer. Cancer 2011;117:795-801.
32. Zhang L, Zhang Y, Huang PY, et al. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. Cancer Chemother Pharmacol 2008;61:33-38. (Pubitemid 47512623)
33. Catimel G, Vermorken JB, Clavel M, et al. A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994;5:543-547. (Pubitemid 24223508)
34. Samlowski WE, Gundacker H, Kuebler JP, et al. Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study. Invest New Drugs 2001;19:311-315. (Pubitemid 32782971)
35. Degardin M, Oliveira J, Geoffrois L, et al. An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 1998;9:1103-1107. (Pubitemid 28518149)
36. Saxman S, Mann B, Canfield V, et al. A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol 1998;21:398-400. (Pubitemid 28366911)
37. Airoldi M, Cortesina G, Giordano C, et al. Ifosfamide in the treatment of head and neck cancer. Oncology 2003;65(Suppl 2):37-43. (Pubitemid 37346728)
38. Murphy BA. Topoisomerases in the treatment of metastatic or recurrent squamous cell carcinoma of the head and neck. Expert Opin Pharmacother 2005;6:85-92.
39. Wittes RE. Chemotherapy of head and neck cancer. Otolaryngol Clin North Am 1980;13:515-520.
40. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-7356. (Pubitemid 36025259)
41. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-832. (Pubitemid 28280548)
42. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5568-5577.
43. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-5587.
44. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based chemotherapy. J Clin Oncol 2007;25:2171-2177. (Pubitemid 46954639)
45. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer. J Clin Oncol 2005;23:8646-8654. (Pubitemid 46211507)
46. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. New Engl J Med 2008;359:1116-1127.
47. Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010;28:8-14.
48. Klinghammer K, Knodler M, Schmittel A, et al. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 2010;16:304-310.
49. Licitra L, Mesia R, Rivera F, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol, in press.
50. Yarbrough WG, Shores C, Witsell DL, et al. ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope 1994;104:1337-1347. (Pubitemid 24346961)
51. Anderson JA, Irish JC, Ngan BY. Prevalence of RAS oncogene mutation in head and neck carcinomas. J Otolaryngol 1992;21:321-326.
52. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 2006;42:109-111. (Pubitemid 41814540)
53. Lee JW, Soung YH, Kim SW, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res 2005;11:2879-2882.
54. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor recepor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12:5064-5073. (Pubitemid 44453332)
55. Tabernero J, Ciardiello F, Rivera F, et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose escalation cetuximab. Ann Oncol 2010;21:1537-1545.
56. 2 every other week for recurrent or metastatic head and neck squamous cell cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00661427. Accessed April 6, 2011.
57. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21:1980-1987. (Pubitemid 46606387)
58. Stewart JWS, Cohen EEW, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1864-1871.
59. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85. (Pubitemid 41095117)
60. Kyzas PA, Cunha IW, Ionnidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 2005;11:1434-1440. (Pubitemid 40315223)
61. Machiels J-PH, Henry S, Zanetta S, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010;28:21-28.
62. Williamson SK, Moon J, Huang CH, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0420. J Clin Oncol 2010;28:3330-3335.
63. Cohen EEW, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009;10:247-257.
64. Molinolo AA, Hewitt SM, Amornphimoltham P, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the Head and Neck Cancer Tissue Array Initiative. Clin Cancer Res 2007;13:4964-4973. (Pubitemid 47502060)
65. Figlin RA, Brown E, Armstrong AJ, et al. NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw 2008;6(Suppl 5):S1-22.
66. Ekshyyan O, Rong Y, Rong X, et al. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 2009;8:2255-2265.
67. Raimondi AR, Molinolo A, Gutkind JS. Rapamycin prevents early onset of carcinogenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Cancer Res 2009;69:4159-4166.
68. Ekshyyan O, Mills GM, Lian T, et al. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced stage head and neck squamous cell carcinoma. Head Neck 2010;32:1619-1628.
69. Shi Y, Frankel A, Radvanyi LG, et al. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995;55:1982-1988.
70. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damage induced apoptosis though inhibition of p21 translation. Cell 2005;120:747-759. (Pubitemid 40568794)
71. Aissat N, Le Tourneau C, Ghoul A, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008;62:305-313. (Pubitemid 351692089)